University of Hertfordshire

  • C. Hawley
  • T.M. Gale
  • T. Sivakumaran
View graph of relations
Original languageEnglish
Pages (from-to)181-187
JournalJournal of Affective Disorders
Volume71
Issue1-3
DOIs
Publication statusPublished - 2002

Abstract

Background: This paper describes the relationship between entry criteria and eligible population for inclusion in Major Depression (MD) clinical trials. Inclusion criteria for a MD study typically require patients to pass a threshold score on a depression rating scale, most commonly the HAM-D or MÅDRS. A Score To Enter (STE) of ≥17 on the HAM-D 17-item scale is a typical value, although higher values (i.e. ≥22 or even ≥25 points) are often used. It is commonly supposed that patients with higher baseline scores form a more sensitive sample for discriminating active drug from placebo. Method: We present data from a sample of depressed hospital outpatients and describe their general characteristics. We then introduce a model, based upon this sample, which predicts the impact of STE on eligible trial population. Results and conclusion: A small increase in STE has a marked effect on eligible population: an increase in HAM-D (17 item) STE from 17 to 21 and 25 reduces the eligible population by 42 and 76%, respectively. These predictions are reasonably robust when our model is validated with known clinical trial data. Clinical relevance: Our findings have major implications for planning and managing Major Depression trials as higher STEs substantially restrict the proportion of patient eligible for study.

Notes

Original article can be found at: http://www.sciencedirect.com/science/journal/01650327 Copyright Elsevier Inc. [Full text of this article is not available in the UHRA]

ID: 193128